Forside  
Velg data du ønsker med i utskriften
Tittel Versjon Status
IS-nr ISBN
Utgiver(e) Publikasjonstype
  • Norsk tittel - Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft
  • Engelsk tittel -
  • Versjon - 1
  • Status - Publisert
  • IS-nr - IS-2462
  • ISBN - 978-82-8081-434-0
  • DOI -
  • Revisjonsdato -
  • Neste revisjon -
  • Publikasjonsdato -
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør -
  • Publikasjonstype - Nasjonale retningslinjer
 
  1. Pakkeforløp for livmorkreft rev. utg. Oslo: Helsedirektoratet; 2016. IS-2353. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/pakkeforlop-for-livmorkreft
  2. Pakkeforløp for eggstokkreft. rev. utg. Oslo: Helsedirektoratet; 2016. IS-2352. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/pakkeforlop-for-eggstokkreft
  3. Pakkeforløp for livmorhalskreft rev. utg. Oslo: Helsedirektoratet; 2016. IS-2354. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/pakkeforlop-for-livmorhalskreft
  4. Lov om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven). LOV-1999-07-02-63.
  5. Forskrift om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften). FOR-2000-12-01-1208.
  6. Larsen IK, red. Cancer in Norway 2012: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2014. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2012/cin_2012-web.pdf
  7. Wijnen J, de Leeuw W, Vasen H, van der Klift H, Moller P, Stormorken A, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999;23(2):142–4.
  8. Kvåle G, Heuch I, Ursin G. Reproductive factors and risk of cancer of the uterine corpus: a prospective study. Cancer Res 1988;48(21):6217–21.
  9. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89(15):1110–6.
  10. Weiderpass E, Baron JA, Adami HO, Magnusson C, Lindgren A, Bergstrom R, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999;353(9167):1824–8.
  11. Committee on Gynecologic Practice. Tamoxifen and uterine cancer. Washington, DC: American College of Obstetricians and Gynecologists; 2014. Committee Opinion no 601. Tilgjengelig fra: http://www.acog.org/-/media/Committee-Opinions/Committee-on-Gynecologic-Practice/co601.pdf?dmc=1&ts=20150203T1931301384
  12. Kinkel K, Kaji Y, Yu KK, Segal MR, Lu Y, Powell CB, et al. Radiologic staging in patients with endometrial cancer: a meta-analysis. Radiology 1999;212(3):711–8.
  13. Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000;89(8):1765–72.
  14. Goldchmit R, Katz Z, Blickstein I, Caspi B, Dgani R. The accuracy of endometrial Pipelle sampling with and without sonographic measurement of endometrial thickness. Obstet Gynecol 1993;82(5):727–30.
  15. Stefansson IM, Salvesen HB, Immervoll H, Akslen LA. Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 2004;44(5):472–9.
  16. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105(2):103–4.
  17. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006;296(12):1507–17.
  18. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354(3):261–9.
  19. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009;27(32):5331–6.
  20. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335(9):640–9.
  21. Galaal K, Bryant A, Fisher AD, Al-Khaduri M, Kew F, Lopes AD. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 2012;(9):Cd006655.
  22. Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 2006;107(8):1823–30.
  23. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2010;(1):Cd007585.
  24. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60(8 Suppl):2035–41.
  25. Johnson N, Bryant A, Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev 2011;(10):Cd003175.
  26. Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer 2010;46(13):2422–31.
  27. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56(4):419–27.
  28. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355(9213):1404–11.
  29. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev 2012;(4):Cd003916.
  30. Martin-Hirsch PP, Bryant A, Keep SL, Kitchener HC, Lilford R. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev 2011;(6):Cd001040.
  31. Vergote I, Kjørstad K, Abeler V, Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 1989;64(5):1011–6.
  32. Njølstad TS, Trovik J, Hveem TS, Kjæreng ML, Kildal W, Pradhan M, et al. DNA ploidy in curettage specimens identifies high-risk patients and lymph node metastasis in endometrial cancer. Br J Cancer 2015;112(10):1656–64.
  33. Salvesen HB, Haldorsen IS, Trovik J. Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 2012;13(8):e353–61.
  34. Trovik J, Wik E, Werner HM, Krakstad C, Helland H, Vandenput I, et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur J Cancer 2013;49(16):3431–41.
  35. ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373(9658):125–36.
  36. Trimble EL, Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 1998;71(3):340–3.
  37. Vale CL, Tierney J, Bull SJ, Symonds PR. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 2012;(8):Cd003915.
  38. Abeler VM, Kjørstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer 1991;67(12):3093–103.
  39. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol 1999;17(5):1382–90.
  40. Iversen OE. Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 1986;155(4):770–6.
  41. Salvesen HB, Akslen LA, Iversen T, Iversen OE. Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol 1997;104(11):1302–7.
  42. Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A, Oliver T, et al. Follow-up after primary therapy for endometrial cancer. Toronto (ON): Program in Evidence-based Care og Cancer Care Ontario; 2006. Evidence-based Series 4–9 IN REVIEW. Tilgjengelig fra: https://www.cancercare.on.ca/common/pages/UserFile.aspx?serverId=6&path=/File%20Database/CCO%20Files/PEBC/pebc4-9f.pdf
  43. Peng X, Fu J, Lina H. Hormone replacement therapy for women previously treated for endometrial cancer [Protocol]. Cochrane Database Syst Rev 2010;(11):CD008830.
  44. Moore TD, Phillips PH, Nerenstone SR, Cheson BD. Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol 1991;9(6):1071–88.
  45. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005;366(9484):491–505.
  46. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi33-8.
  47. Uterussarkom I: Veileder i gynekologisk onkologi. Trondheim/Bergen/Oslo: Norsk gynekologisk forening; 2009. Tilgjengelig fra: http://legeforeningen.no/Fagmed/Norsk-gynekologisk-forening/Veiledere/veileder-i-gynekologisk-onkologi-2009/uterussarkom/
  48. Palliasjon i kreftomsorgen: nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen Oslo: Helsedirektoratet; 2015. IS-2285. Tilgjengelig fra: https://helsedirektoratet.no/Sider/Nasjonalt-handlingsprogram-med-retningslinjer-for-palliasjon-i-kreftomsorgen.aspx
  49. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol 2012;226(3):421–6.
  50. Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol 2013;42(2):579–89.
  51. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34(3):433–43.
  52. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of Tumours of Female Reproductive Organs. 4. utg. Lyon: IARC; 2014.
  53. Larsen IK, red. Cancer in Norway 2013: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2015. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2013/cin_2013.pdf
  54. Tropé CG, Davidson B, Dørum A, Kærn J, Kristensen GB, Paulsen T, et al. Epithelial ovarian cancer. I: Peltecu GC, Tropé CG, red. Gynecol Oncol. Bucharest: The Publishing House of the Romanian Academy; 2010. s. 357–444.
  55. Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 2008;108(3):641–51.
  56. Modan B, Hartge P, Hirsh-Yechezkel G, Chetrit A, Lubin F, Beller U, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345(4):235–40.
  57. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357(9251):176–82.
  58. Paulsen T, Kærn J, Trope C. Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery. Gynecol Oncol 2011;122(1):83–8.
  59. Winter WE, 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25(24):3621–7.
  60. Harrison ML, Jameson C, Gore ME. Mucinous ovarian cancer. Int J Gynecol Cancer 2008;18(2):209–14.
  61. Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008;99(4):653–8.
  62. Makar AP, Kristensen GB, Børmer OP, Trope CG. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. Gynecol Oncol 1993;49(1):73–9.
  63. Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109(2):221–7.
  64. Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992;79(6):1002–10.
  65. Langmar Z, Nemeth M, Vlesko G, Kiraly M, Hornyak L, Bosze P. HE4--a novel promising serum marker in the diagnosis of ovarian carcinoma. Eur J Gynaecol Oncol 2011;32(6):605–10.
  66. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999;93(3):448–52.
  67. Decloedt J, Vergote I. Laparoscopy in gynaecologic oncology: a review. Crit Rev Oncol Hematol 1999;31(1):15–26.
  68. Prat J. FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol 2015;26(2):87–9.
  69. Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol 2007;105(3):801–12.
  70. Giede KC, Kieser K, Dodge J, Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol Oncol 2005;99(2):447–61.
  71. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 2006;16 Suppl 1:11–7.
  72. ristow RE, Santillan A, Diaz-Montes TP, Gardner GJ, Giuntoli RL, 2nd, Meisner BC, et al. Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. Cancer 2007;109(8):1513–22.
  73. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol 2006;103(2):559–64.
  74. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003;95(2):113–25.
  75. Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer 2007;96(12):1817–22.
  76. ristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007;104(2):480–90.
  77. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P, Bryant A. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2016;(1):Cd006014.
  78. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363(10):943–53.
  79. Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer 2013;23(9):1603–11.
  80. Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer 2011;21(5):846–51.
  81. Kristensen GB, Kildal W, Abeler VM, Kærn J, Vergote I, Trope CG, et al. Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer. Ann Oncol 2003;14(10):1494–500.
  82. Hoskins WJ. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 1993;71(4 Suppl):1534–40.
  83. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011;(8):Cd007565.
  84. Paulsen T, Kærn J, Kjærheim K, Haldorsen T, Tropé C. Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer. Gynecol Oncol 2006;102(3):447–52.
  85. Trope C, Kærn J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J Clin Oncol 2007;25(20):2909–20.
  86. Elit L, Chambers A, Fyles A, Covens A, Carey M, Fung MF. Systematic review of adjuvant care for women with Stage I ovarian carcinoma. Cancer 2004;101(9):1926–35.
  87. Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, et al. Ovarian cancer. Crit Rev Oncol Hematol 2006;60(2):159–79.
  88. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer 2012;48(15):2361–8.
  89. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473–83.
  90. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484–96.
  91. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 2006;13(12):1702–10.
  92. Oksefjell H, Sandstad B, Trope C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol 2009;20(2):286–93.
  93. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 2009;112(1):265–74.
  94. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007;14(5):195–208.
  95. Havrilesky LJ, Secord AA, Kulasingam S, Myers E. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis. Gynecol Oncol 2007;107(2):211–8.
  96. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366(15):1382–92.
  97. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15(8):852–61.
  98. Rao GG, Miller DS. Hormonal therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther 2006;6(1):43–7.
  99. Eric PL, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). Journal of Clinical Oncology Conference 2012;30(18 SUPPL. 1):LBA5002.
  100. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376(9747):1155–63.
  101. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004;96(6):487–8.
  102. Liavaag AH, Dørum A, Fosså SD, Trope C, Dahl AA. Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol 2007;25(15):2049–56.
  103. Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 2000;92(18):1534–5.
  104. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 Suppl 1:S161–92.
  105. Søgaard M, Kjær SK, Gayther S. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. Acta Obstet Gynecol Scand 2006;85(1):93–105.
  106. Lagerstedt Robinson K, Liu T, Vandrovcova J, Halvarsson B, Clendenning M, Frebourg T, et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 2007;99(4):291–9.
  107. Liebens FP, Carly B, Pastijn A, Rozenberg S. Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer 2007;43(2):238–57.
  108. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25(11):1329–33.
  109. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117–30.
  110. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004;10(7):2473–81.
  111. Piver MS. Hereditary ovarian cancer. Lessons from the first twenty years of the Gilda Radner Familial Ovarian Cancer Registry. Gynecol Oncol 2002;85(1):9–17.
  112. Farrell C, Lyman M, Freitag K, Fahey C, Piver MS, Rodabaugh KJ. The role of hereditary nonpolyposis colorectal cancer in the management of familial ovarian cancer. Genet Med 2006;8(10):653–7.
  113. Broaddus RR, Lynch HT, Chen LM, Daniels MS, Conrad P, Munsell MF, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006;106(1):87–94.
  114. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104(12):2807–16.
  115. Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med (Berl) 2006;84(1):16–28.
  116. Handlingsprogram for brystkreft. rev. utg. Oslo: Helsedirektoratet; 2016. IS-2440. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-diagnostikk-behandling-og-oppfolging-av-pasienter-med-brystkreft
  117. Guidelines for familial high-risk assessment breast and ovarian cancer. Fort Washington, PA: National Comprehencive Cancer Network; 2014.
  118. Kehoe SM, Kauff ND. Screening and prevention of hereditary gynecologic cancers. Semin Oncol 2007;34(5):406–10.
  119. Sharma A, Menon U. Screening for gynaecological cancers. Eur J Surg Oncol 2006;32(8):818–24.
  120. Tailor A, Bourne TH, Campbell S, Okokon E, Dew T, Collins WP. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol 2003;21(4):378–85.
  121. Barakat R, Hensley ML, Bhaskaran D, Rastogi P, Korytowsky B, Boyd J, et al. Prophylactic Oophorectomy in Patients at Risk for Hereditary Ovarian Carcinoma. Gynecol Oncol 2002;84(3):482.
  122. Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32(15):1547–53.
  123. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006;24(22):3576–82.
  124. Lobo RA. Surgical menopause and cardiovascular risks. Menopause 2007;14(3 Pt 2):562–6.
  125. Dørum A, Tonstad S, Liavaag AH, Michelsen TM, Hildrum B, Dahl AA. Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2). Gynecol Oncol 2008;109(3):377–83.
  126. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26(8):1331–7.
  127. Backes FJ. Salpingectomy, why not? Am J Obstet Gynecol 2014;210(5):385–6.
  128. McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014;210(5):471.e1-11.
  129. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol 2011;42(7):918–31.
  130. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007;8(1):26–34.
  131. Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 1993;270(23):2813–8.
  132. Peccatori F, Bonazzi C, Chiari S, Landoni F, Colombo N, Mangioni C. Surgical management of malignant ovarian germ-cell tumors: 10 years’ experience of 129 patients. Obstet Gynecol 1995;86(3):367–72.
  133. Gershenson DM. Update on malignant ovarian germ cell tumors. Cancer 1993;71(4 Suppl):1581–90.
  134. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol 2007;25(20):2938–43.
  135. Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999;17(9):2670–75.
  136. Berek JS, Hacker NF. Nonepitelial ovarian and fallopian tube cancers. I: Berek JS, Hacker NF, red. Practical Gynecologic Oncology. Philadelphia: Lippincott Williams & Wilkins; 2010. s. 509–36.
  137. Colombo N, Parma G, Zanagnolo V, Insinga A. Management of ovarian stromal cell tumors. J Clin Oncol 2007;25(20):2944–51.
  138. Williams S. I: Gershenson DM, McGuire WP, red. Ovarian Cancer: Controversies in Management. New York: Churchil Livingstone; 1998. s. 403–4.
  139. Abu-Rustum NR, Aghajanian C. Management of malignant germ cell tumors of the ovary. Semin Oncol 1998;25(2):235–42.
  140. Billmire D, Vinocur C, Rescorla F, Cushing B, London W, Schlatter M, et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J Pediatr Surg 2004;39(3):424–9; discussion -9.
  141. Sehouli J, Drescher FS, Mustea A, Elling D, Friedmann W, Kuhn W, et al. Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res 2004;24(2c):1223–9.
  142. Ovarian cancer. Version 3.2014. Fort Washington, PA: National Comprehencive Cancer Network; 2014.
  143. Harter P, Gershenson D, Lhomme C, Lecuru F, Ledermann J, Provencher DM, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors). Int J Gynecol Cancer 2014;24(9 Suppl 3):S5–8.
  144. Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124(1):1–5.
  145. Nasjonalt kvalitetsregister for gynekologisk kreft: årsrapport 2013–2014. Oslo: Kreftregisteret; 2015. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/arsrapporter/2015/aarsrapport_2015_gynekologisk_kreft-.pdf
  146. Burger CW, Van De Swaluw A, Mooij TM, Van Leeuwen FE. Risk of borderline and invasive ovarian tumors after ovarian stimulation for in vitro fertilization in a large Dutch cohort after 15 years of follow-up. Gynecol Oncol 2009;1):S4-S5.
  147. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 2001;83(3):575–85.
  148. Fortin A, Morice P, Thoury A, Camatte S, Dhainaut C, Madelenat P. Impact of infertility drugs after treatment of borderline ovarian tumors: results of a retrospective multicenter study. Fertil Steril 2007;87(3):591–6.
  149. Bjørge T, Engeland A, Hansen S, Tropé CG. Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int J Cancer 1998;75(5):663–70.
  150. Paulsen T. Epithelial ovarian cancer: a clinical epidemiological approach on diagnosis and treatment [doktorgrad]. Oslo: University of Oslo; 2007. Series of dissertations submitted to the Faculty of Medicine, University of Oslo No.549. Tilgjengelig fra: https://www.duo.uio.no/handle/10852/28083
  151. Paulsen T, Kærn J, Kjærheim K, Tropé C, Tretli S. Symptoms and referral of women with epithelial ovarian tumors. Int J Gynaecol Obstet 2005;88(1):31–7.
  152. Bois AD, Ewald-Riegler N, Bois OD, Harter P. Borderline-tumoren des ovars – Eine systematische ubersicht. Geburtshilfe Frauenheilkd 2009;69(9):807–33.
  153. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clin Oncol 2007;25(20):2928–37.
  154. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000;31(5):539–57.
  155. Camatte S, Morice P, Thoury A, Fourchotte V, Pautier P, Lhomme C, et al. Impact of surgical staging in patients with macroscopic «stage I» ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer 2004;40(12):1842–9.
  156. Jones MB. Borderline ovarian tumors: current concepts for prognostic factors and clinical management. Clin Obstet Gynecol 2006;49(3):517–25.
  157. Trillsch F, Mahner S, Ruetzel J, Harter P, Ewald-Riegler N, Jaenicke F, et al. Clinical management of borderline ovarian tumors. Expert Rev Anticancer Ther 2010;10(7):1115–24.
  158. Tropé C, Davidson B, Paulsen T, Abeler VM, Kærn J. Diagnosis and treatment of borderline ovarian neoplasms «the state of the art». Eur J Gynaecol Oncol 2009;30(5):471–82.
  159. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 2008;198(4):351–6.
  160. Ødegaard E, Staff AC, Langebrekke A, Engh V, Onsrud M. Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy. Acta Obstet Gynecol Scand 2007;86(5):620–6.
  161. Morice P, Camatte S, Wicart-Poque F, Atallah D, Rouzier R, Pautier P, et al. Results of conservative management of epithelial malignant and borderline ovarian tumours. Hum Reprod Update 2003;9(2):185–92.
  162. Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A. Conservative surgery for borderline ovarian tumors: a review. Gynecol Oncol 2006;100(1):185–91.
  163. Fauvet R, Boccara J, Dufournet C, Poncelet C, Darai E. Laparoscopic management of borderline ovarian tumors: results of a French multicenter study. Ann Oncol 2005;16(3):403–10.
  164. Vandenput I, Amant F, Vergote I. Peritoneal recurrences might be less common in advanced stage serous borderline ovarian tumors that were treated by laparotomy. Gynecol Oncol 2005;98(3):523; author reply 4–5.
  165. Tropé C, Kærn J, Vergote IB, Kristensen G, Abeler V. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 1993;51(2):236–43.
  166. Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol 2005;29(6):707–23.
  167. Silva EG, Gershenson DM, Malpica A, Deavers M. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. Am J Surg Pathol 2006;30(11):1367–71.
  168. Gershenson DM, Silva EG. Serous ovarian tumors of low malignant potential with peritoneal implants. Cancer 1990;65(3):578–85.
  169. Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 2004;100(5):1045–52.
  170. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348(6):518–27.
  171. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24 Suppl 3:S3/1–10.
  172. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010;117(2 Suppl):S5–10.
  173. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest 2011;121(12):4593–9.
  174. Schiffman M, Wentzensen N. From human papillomavirus to cervical cancer. Obstet Gynecol 2010;116(1):177–85.
  175. Gadducci A, Barsotti C, Cosio S, Domenici L, Riccardo Genazzani A. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol 2011;27(8):597–604.
  176. Kjellberg L, Hallmans G, Ahren AM, Johansson R, Bergman F, Wadell G, et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 2000;82(7):1332–8.
  177. Vaccarella S, Herrero R, Snijders PJ, Dai M, Thomas JO, Hieu NT, et al. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol 2008;37(3):536–46.
  178. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006;118(6):1481–95.
  179. Jordan J, Martin-Hirsch P, Arbyn M, Schenck U, Baldauf JJ, Da Silva D, et al. European guidelines for clinical management of abnormal cervical cytology, part 2. Cytopathology 2009;20(1):5–16.
  180. Dillner J, Kallings I, Brihmer C, Sikström B, Koskela P, Lehtinen M, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996;173(6):1394–8.
  181. de Araujo Souza PS, Sichero L, Maciag PC. HPV variants and HLA polymorphisms: the role of variability on the risk of cervical cancer. Future Oncol 2009;5(3):359–70.
  182. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30 Suppl 5:F12–23.
  183. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. Lyon: IARC; 2007. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Vol. 90. Tilgjengelig fra: http://monographs.iarc.fr/ENG/Monographs/vol90/mono90.pdf
  184. Masseundersøkelsen mot livmorhalskreft: årsrapport 2012. Oslo: Kreftregisteret; 2014. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/livmorhalskreft/aarsrapport_livmorhals_2012.pdf
  185. Patel S, Liyanage SH, Sahdev A, Rockall AG, Reznek RH. Imaging of endometrial and cervical cancer. Insights into imaging 2010;1(5–6):309–28.
  186. FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet 2014;125(2):97–8.
  187. Zaino RJ, Ward S, Delgado G, Bundy B, Gore H, Fetter G, et al. Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Cancer 1992;69(7):1750–8.
  188. Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology 2002;41(3):185–207.
  189. Bjørge T, Thoresen SO, Skare GB. Incidence, survival and mortality in cervical cancer in Norway, 1956–1990. Eur J Cancer 1993;29a(16):2291–7.
  190. Alfsen GC, Kristensen GB, Skovlund E, Pettersen EO, Abeler VM. Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix. Cancer 2001;92(9):2471–83.
  191. Alfsen GC, Reed W, Abeler VM. Reproducibility of classification in non-squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2003;90(2):282–9.
  192. Soutter WP, Haidopoulos D, Gornall RJ, McIndoe GA, Fox J, Mason WP, et al. Is conservative treatment for adenocarcinoma in situ of the cervix safe? BJOG 2001;108(11):1184–9.
  193. Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Long HJ, 3rd, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 2015;16(3):301–11.
  194. Peters WA, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18(8):1606–13.
  195. Martimbeau PW, Kjørstad KE, Kolstad P. Stage IB carcinoma of the cervix, the Norwegian Radium Hospital, 1968–1970: results of treatment and major complications. I. Lymphedema. Am J Obstet Gynecol 1978;131(4):389–94.
  196. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 1999;73(2):177–83.
  197. Van de Putte G, Lie AK, Vach W, Baekelandt M, Kristensen GB. Risk grouping in stage IB squamous cell cervical carcinoma. Gynecol Oncol 2005;99(1):106–12.
  198. Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix. Int J Gynecol Cancer 2014;24(9 Suppl 3):S102–8.
  199. Plante M. Evolution in fertility-preserving options for early-stage cervical cancer: radical trachelectomy, simple trachelectomy, neoadjuvant chemotherapy. Int J Gynecol Cancer 2013;23(6):982–9.
  200. Bouchard-Fortier G, Reade CJ, Covens A. Non-radical surgery for small early-stage cervical cancer. Is it time? Gynecol Oncol 2014;132(3):624–7.
  201. Amant F, Halaska MJ, Fumagalli M, Dahl Steffensen K, Lok C, Van Calsteren K, et al. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer 2014;24(3):394–403.
  202. Kucukmetin A, Biliatis I, Naik R, Bryant A. Laparoscopically assisted radical vaginal hysterectomy versus radical abdominal hysterectomy for the treatment of early cervical cancer. Cochrane Database Syst Rev 2013;(10):Cd006651.
  203. Frøding LP, Ottosen C, Mosgaard BJ, Jensen PT. Quality of life, urogynecological morbidity, and lymphedema after radical vaginal trachelectomy for early-stage cervical cancer. Int J Gynecol Cancer 2015;25(4):699–706.
  204. Halaska MJ, Novackova M, Mala I, Pluta M, Chmel R, Stankusova H, et al. A prospective study of postoperative lymphedema after surgery for cervical cancer. Int J Gynecol Cancer 2010;20(5):900–4.
  205. Frøding LP, Ottosen C, Rung-Hansen H, Svane D, Mosgaard BJ, Jensen PT. Sexual functioning and vaginal changes after radical vaginal trachelectomy in early stage cervical cancer patients: a longitudinal study. J Sex Med 2014;11(2):595–604.
  206. Vistad I, Cvancarova M, Fosså SD, Kristensen GB. Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians’ assessments agree with those of their patients? Int J Radiat Oncol Biol Phys 2008;71(5):1335–42.
  207. Kim JH, Choi JH, Ki EY, Lee SJ, Yoon JH, Lee KH, et al. Incidence and risk factors of lower-extremity lymphedema after radical surgery with or without adjuvant radiotherapy in patients with FIGO stage I to stage IIA cervical cancer. Int J Gynecol Cancer 2012;22(4):686–91.
  208. Vistad I, Cvancarova M, Kristensen GB, Fosså SD. A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer. J Cancer Surviv 2011;5(2):208–16.
  209. Vistad I, Kristensen GB, Fosså SD, Dahl AA, Mørkrid L. Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2009;73(4):1141–7.
  210. Kristensen GB. Studies on prognostic factors in cervical cancer with special attention to early disease [doktorgrad]. Oslo: University of Oslo; 1999.
  211. Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287(16):2114–9.
  212. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005;191(11):1808–16.
  213. Skjeldestad FE, Mehta V, Sings HL, Øvreness T, Turpin J, Su L, et al. Seroprevalence and genital DNA prevalence of HPV types 6, 11, 16 and 18 in a cohort of young Norwegian women: study design and cohort characteristics. Acta Obstet Gynecol Scand 2008;87(1):81–8.
  214. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol 2009;10(4):321–2.
  215. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 2003;361(9364):1159–67.
  216. Silins I, Ryd W, Strand A, Wadell G, Tornberg S, Hansson BG, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005;116(1):110–5.
  217. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9(5):425–34.
  218. Albrechtsen S, Rasmussen S, Thoresen S, Irgens LM, Iversen OE. Pregnancy outcome in women before and after cervical conisation: population based cohort study. BMJ 2008;337:a1343.
  219. Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009;113(1):18–25.
  220. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24 Suppl 3:S3/78–89.
  221. Ghaem-Maghami S, Soutter WP. Re: Effect of margin status on cervical intraepithelial neoplasia recurrence following LLETZ in women over 50 years. BJOG 2009;116(3):465.
  222. Paraskevaidis E, Jandial L, Mann EM, Fisher PM, Kitchener HC. Pattern of treatment failure following laser for cervical intraepithelial neoplasia: implications for follow-up protocol. Obstet Gynecol 1991;78(1):80–3.
  223. Kocken M, Helmerhorst TJ, Berkhof J, Louwers JA, Nobbenhuis MA, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011;12(5):441–50.
  224. Casper GR, Ostor AG, Quinn MA. A clinicopathologic study of glandular dysplasia of the cervix. Gynecol Oncol 1997;64(1):166–70.
  225. Vaccarella S, Franceschi S, Engholm G, Lönnberg S, Khan S, Bray F. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer 2014;111(5):965–9.
  226. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101(2):88–99.
  227. Arbyn M, Roelens J, Simoens C, Buntinx F, Paraskevaidis E, Martin-Hirsch PP, et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database Syst Rev 2013;(3):Cd008054.
  228. Gage JC, Hanson VW, Abbey K, Dippery S, Gardner S, Kubota J, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006;108(2):264–72.
  229. Guido R, Schiffman M, Solomon D, Burke L, ASCUS LSIL Triage Study (ALTS) Group. Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003;188(6):1401–5.
  230. Pretorius RG, Belinson JL, Burchette RJ, Hu S, Zhang X, Qiao YL. Regardless of skill, performing more biopsies increases the sensitivity of colposcopy. J Low Genit Tract Dis 2011;15(3):180–8.
  231. Ferris DG, Greenberg MD. Reid’s Colposcopic Index. J Fam Pract 1994;39(1):65–70.
  232. Bowring J, Strander B, Young M, Evans H, Walker P. The Swede score: evaluation of a scoring system designed to improve the predictive value of colposcopy. J Low Genit Tract Dis 2010;14(4):301–5.
  233. Tatti S, Bornstein J, Prendiville W. Colposcopy: a global perspective: introduction of the new IFCPC colposcopy terminology. Obstet Gynecol Clin North Am 2013;40(2):235–50.
  234. Tropé C. En forenklet kolposkopiguide. Gynekologen 2014;27(2):35–40.
  235. Högberg U, red. Cervixcancerprevention: riktlinjer för utredning, behandling och uppföljning av cervikal intraepitelial neoplasi (CIN). Umå: Svensk Förening för Obstetrik och Gynekologi; 2010. Arbets- och Referensgruppen för Cervixcancerprevention Nr 63 2010. Tilgjengelig fra: https://www.sfog.se/media/18454/intro_arg63_.pdf
  236. Hunter MI, Monk BJ, Tewari KS. Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease. Am J Obstet Gynecol 2008;199(1):3–9.
  237. Hunter MI, Tewari K, Monk BJ. Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease. Am J Obstet Gynecol 2008;199(1):10–8.
  238. Nygård M, Daltveit AK, Thoresen SO, Nygard JF. Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study. BMC Health Serv Res 2007;7:10.
  239. Kärrberg C, Brannstrom M, Strander B, Ladfors L, Rådberg T. Colposcopically directed cervical biopsy during pregnancy; minor surgical and obstetrical complications and high rates of persistence and regression. Acta Obstet Gynecol Scand 2013;92(6):692–9.
  240. Ackermann S, Gehrsitz C, Mehlhorn G, Beckmann MW. Management and course of histologically verified cervical carcinoma in situ during pregnancy. Acta Obstet Gynecol Scand 2006;85(9):1134–7.
  241. Bruinsma FJ, Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG 2011;118(9):1031–41.
  242. Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol 2010;116(6):1373–80.
  243. Larsen IK, red. Cancer in Norway 2009: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2011. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/cancer-in-norway/cancer_in_norway_2009_and_special_issue.pdf
  244. Skjeldestad FE, Hagen B, Hagmar B, Iversen OE, Juvkam KH, Steen R, et al. Er cervixcytologisk undersøkelse av unge kvinner mer til skade enn til gagn? Tidsskr Nor Laegeforen 2007;127(13):1782–5.
  245. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004;291(17):2100–6.
  246. Nøhr B, Tabor A, Frederiksen K, Kjær SK. Loop electrosurgical excision of the cervix and the subsequent risk of preterm delivery. Acta Obstet Gynecol Scand 2007;86(5):596–603.
  247. Li Z, Zhao C. Long-term follow-up results from women with cervical adenocarcinoma in situ treated by conization: an experience from a large academic women’s hospital. J Low Genit Tract Dis 2013;17(4):452–8.
  248. Hagen B, Skjeldestad FE, Bratt H, Tingulstad S, Lie AK. CO2 laser conization for cervical intraepithelial neoplasia grade II-III: complications and efficacy. Acta Obstet Gynecol Scand 1998;77(5):558–63.
  249. Sjøborg KD, Vistad I, Myhr SS, Svenningsen R, Herzog C, Kloster-Jensen A, et al. Pregnancy outcome after cervical cone excision: a case-control study. Acta Obstet Gynecol Scand 2007;86(4):423–8.
  250. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006;367(9509):489–98.
  251. Iversen O-E, L.E. E, Baasland I, Kirschner R. Premaligne og maligne forandringer i cervix i graviditet I: Øian P, Jacobsen AF, Kessler J, red. Veileder i fødselshjelp 2014. Oslo: Norsk gynekologisk forening; 2014. Tilgjengelig fra: http://legeforeningen.no/Fagmed/Norsk-gynekologisk-forening/Veiledere/Veileder-i-fodselshjelp-2014/Premaligne-og-maligne-forandringer-i-cervix-i-graviditet/
  252. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol 2013;130(2):264–8.
  253. Iversen T, Tretli S. Intraepithelial and invasive squamous cell neoplasia of the vulva: trends in incidence, recurrence, and survival rate in Norway. Obstet Gynecol 1998;91(6):969–72.
  254. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013. Tilgjengelig fra: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf
  255. De Hullu JA, Hollema H, Lolkema S, Boezen M, Boonstra H, Burger MP, et al. Vulvar carcinoma. The price of less radical surgery. Cancer 2002;95(11):2331–8.
  256. Jones RW, Rowan DM. Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma. Obstet Gynecol 1994;84(5):741–5.
  257. de Hullu JA, van der Avoort IA, Oonk MH, van der Zee AG. Management of vulvar cancers. Eur J Surg Oncol 2006;32(8):825–31.
  258. Micheletti L, Preti M. Surgery of the vulva in vulvar cancer. Best Pract Res Clin Obstet Gynaecol 2014;28(7):1074–87.
  259. Iversen T, Abeler V, Aalders J. Individualized treatment of stage I carcinoma of the vulva. Obstet Gynecol 1981;57(1):85–9.
  260. Scheistrøen M, Nesland JM, Trope C. Have patients with early squamous carcinoma of the vulva been overtreated in the past? The Norwegian experience 1977–1991. Eur J Gynaecol Oncol 2002;23(2):93–103.
  261. Woelber L, Kock L, Gieseking F, Petersen C, Trillsch F, Choschzick M, et al. Clinical management of primary vulvar cancer. Eur J Cancer 2011;47(15):2315–21.
  262. Dhakal HP, Nesland JM, Førsund M, Trope CG, Holm R. Primary tumor vascularity, HIF-1alpha and VEGF expression in vulvar squamous cell carcinomas: their relationships with clinicopathological characteristics and prognostic impact. BMC Cancer 2013;13:506.
  263. Knopp S. Prognostic studies in vulvar squamous cell carcinoma: with emphasis on cell cycle components, human papillomavirus and occult metastases [doktorgrad]. Oslo: University of Oslo; 2006. Series of dissertations submitted to the Faculty of Medicine, University of Oslo No. 492.
  264. Smith JS, Backes DM, Hoots BE, Kurman RJ, Pimenta JM. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 2009;113(4):917–24.
  265. Srodon M, Stoler MH, Baber GB, Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 2006;30(12):1513–8.
  266. Edey KA, Allan E, Murdoch JB, Cooper S, Bryant A. Interventions for the treatment of Paget’s disease of the vulva. Cochrane Database Syst Rev 2013;(10):Cd009245.
  267. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 Suppl 1.
  268. Beller U, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Maisonneuve P, et al. Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 Suppl 1:S7-27.
  269. Ansink A, van der Velden J. Surgical interventions for early squamous cell carcinoma of the vulva. Cochrane Database Syst Rev 2000;(2):Cd002036.
  270. Chan JK, Sugiyama V, Pham H, Gu M, Rutgers J, Osann K, et al. Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol 2007;104(3):636–41.
  271. de Hullu JA, van der Zee AG. Surgery and radiotherapy in vulvar cancer. Crit Rev Oncol Hematol 2006;60(1):38–58.
  272. Woelber L, Choschzick M, Eulenburg C, Hager M, Jaenicke F, Gieseking F, et al. Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva. Ann Surg Oncol 2011;18(13):3811–8.
  273. Micheletti L, Bogliatto F, Levi AC. La linfoadenectomia inguino-femorale: fondamenti embriologici, anatomotopografici, anatomochirurgici sulla preservazione della fascia femorale. Roma: CIC Edizioni Internazionali; 2005.
  274. van der Velden J, Fons G, Lawrie TA. Primary groin irradiation versus primary groin surgery for early vulvar cancer. Cochrane Database Syst Rev 2011;(5):CD002224.
  275. Oonk MH, van Hemel BM, Hollema H, de Hullu JA, Ansink AC, Vergote I, et al. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol 2010;11(7):646–52.
  276. Robison K, Roque D, McCourt C, Stuckey A, DiSilvestro PA, Sung CJ, et al. Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy alone. Gynecol Oncol 2014;133(3):416–20.
  277. Levenback C, van der Zee AGJ, Coleman R, red. Clinical lymphatic mapping in gynecologic cancers. London and New York: Taylor & Francis; 2004.
  278. Mahner S, Jueckstock JK, Hilpert F, Lubbe D, Harter P, De Gregorio N, et al. Impact of adjuvant therapy in lymph-node positive vulvar cancer: The AGO CARE 1 study. J Clin Oncol 2012;30(15 SUPPL. 1):abstract 5007.
  279. Gaarenstroom KN, Kenter GG, Trimbos JB, Agous I, Amant F, Peters AA, et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer 2003;13(4):522–7.
  280. Larson B, Tholander B, red. Björkholm E. Vulvacancer. Stockholm: Svenska läkaresällskapet; 2000. Rapport / Svensk förenings för obstetrik och gynekologi arbets- och referensgrupp nr. 44.
  281. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006;107(5):1018–22.
  282. Kokka F, Singh N, Faruqi A, Gibbon K, Rosenthal AN. Is differentiated vulval intraepithelial neoplasia the precursor lesion of human papillomavirus-negative vulval squamous cell carcinoma? Int J Gynecol Cancer 2011;21(7):1297–305.
  283. Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol 2005;106(6):1319–26.
  284. van Seters M, van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol 2005;97(2):645–51.
  285. Holschneider CH. Vulvar intraepithial neoplasia. UpToDate [database]. Waltham, MA: UoToDate, Inc [oppdatert 7. november 2014; lest 23. juni 2016].
  286. Terlou A, Blok LJ, Helmerhorst TJ, van Beurden M. Premalignant epithelial disorders of the vulva: squamous vulvar intraepithelial neoplasia, vulvar Paget’s disease and melanoma in situ. Acta Obstet Gynecol Scand 2010;89(6):741–8.
  287. Jones RW. Vulval intraepithelial neoplasia: current perspectives. Eur J Gynaecol Oncol 2001;22(6):393–402.
  288. Preti M, Van Seters M, Sideri M, Van Beurden M. Squamous vulvar intraepithelial neoplasia. Clin Obstet Gynecol 2005;48(4):845–61.
  289. Hørding U, Junge J, Poulsen H, Lundvall F. Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential. Gynecol Oncol 1995;56(2):276–9.
  290. Ferris DG, Cox JT, O’Connor DM, Wright VC, Foerster J. Modern colposcopy: textbook and atlas. 2. utg. Dubuque, Iowa: Kendall/Hunt; 2004.
  291. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010;102(5):325–39.
  292. Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. Obstet Gynecol 2006;108(6):1361–8.
  293. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361(19):1838–47.
  294. Lai KW, Mercurio MG. Medical and surgical approaches to vulvar intraepithelial neoplasia. Dermatol Ther 2010;23(5):477–84.
  295. Clinical Effectiveness Group, British Association for Sexual Health and HIV. 2014 UK national guideline on the management of vulval conditions. London: British Association for Sexual Health and HIV; 2014. Tilgjengelig fra: http://www.bashh.org/documents/UK%20national%20guideline%20for%20the%20management%20of%20vulval%20conditions%202014.pdf 
  296. Pepas L, Kaushik S, Nordin A, Bryant A, Lawrie TA. Medical interventions for high-grade vulval intraepithelial neoplasia. Cochrane Database Syst Rev 2015;(8):Cd007924.
  297. Berkowitz RS, Goldstein DP. Gestational Trophoblastic Neoplasia. I: Berek JS, Hacker NF, red. Practical gynecologic oncology. 2. utg. Baltimore: Williams & Wilkins; 1994. s. 457–78.
  298. Hancock BW, Seckl MJ, Berkowitz RS, red. Gestational trophoblastic disease. 4. utg. [s.l.]: International Society for the Study of Trophoblastic Diseases; 2015. Tilgjengelig fra: http://isstd.org/gtd-book/front-page/
  299. Soper JT, Lewis Jr JL, Hammond C. Gestational Trophoblastic Disease. I: Hoskins WJ, Perez CA, Toung R, red. Principles and practice of gynecologic oncology. 4 utg. Philadelphia: Lippincott Williams & Wilkins; 2005. s. 1039–77.
  300. Kohorn EI. The trophoblastic Tower of Babel: classification systems for metastatic gestational trophoblastic neoplasia. Gynecol Oncol 1995;56(2):280–8.
  301. Gamer EI, Garrett A, Goldstein DP, Berkowitz RS. Significance of chest computed tomography findings in the evaluation and treatment of persistent gestational trophoblastic neoplasia. J Reprod Med 2004;49(6):411–4.
  302. Goldstein DP, Berkowitz RS. Management of molar pregnancy and gestational trophoblastic neoplasms. I: Peltecu GC, Tropé CG, red. Gynecol Oncol. Bucharest  Publishing House of the Romanian Academy; 2010. s. 483–94.
  303. Seckl MJ, Sebire NJ, Berkowitz RS. Gestational trophoblastic disease. Lancet 2010;376(9742):717–29.
  304. Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol 2011;29(7):825–31.
  305. May T, Goldstein DP, Berkowitz RS. Current chemotherapeutic management of patients with gestational trophoblastic neoplasia. Chemotherapy research and practice 2011;2011:806256.
  306. Kohorn EI. Evaluation of the criteria used to make the diagnosis of nonmetastatic gestational trophoblastic neoplasia. Gynecol Oncol 1993;48(2):139–47.
  307. Oncolex, Onkologisk oppslagsverk [database]. Oslo: Oslo universitetssykehus HF [oppdatert 2016; lest 23. juni 2016]. Tilgjengelig fra: http://oncolex.no/
  308. Lurain JR, Singh DK, Schink JC. Role of surgery in the management of high-risk gestational trophoblastic neoplasia. J Reprod Med 2006;51(10):773–6.
  309. Baergen RN, Rutgers JL, Young RH, Osann K, Scully RE. Placental site trophoblastic tumor: A study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol 2006;100(3):511–20.
  310. Palmer JE, Macdonald M, Wells M, Hancock BW, Tidy JA. Epithelioid trophoblastic tumor: a review of the literature. J Reprod Med 2008;53(7):465–75.
  311. Nasjonal helseplan (2007–2010). Oslo: Helse- og omsorgsdepartementet; 2006. Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6. Tilgjengelig fra: https://www.regjeringen.no/globalassets/upload/HOD/Sykehus/Nasjonal_helseplan_Sartrykk.pdf 
  312. Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). LOV-2011-06-24-30.
  313. Veileder i onkologisk gynekologi 2002. Oslo: Norsk gynekologisk forening; 2002. Tilgjengelig fra: http://legeforeningen.no/Fagmed/Norsk-gynekologisk-forening/Veiledere/veileder-i-onkologisk-gynekologi-2002/
  314. Sammen mot kreft: nasjonal kreftstrategi 2013–2017. Oslo: Helse- og omsorgsdepartementet; 2013. Tilgjengelig fra: https://www.regjeringen.no/contentassets/07cd14ff763444a3997de1570b85fad1/kreftstrategien_2013.pdf